JP-2022537887-A5 -

Dates

Publication Date

20230526

Application Date

20200519

Description

10. Invocation by Reference All publications, patents, patent applications and other documents cited herein are incorporated herein by reference in whole for all purposes to the same extent that each individual publication, patent, patent application or other document is individually indicated as being incorporated by reference for all purposes. If there is any conflict between one or more of the references incorporated herein and the teachings of this disclosure, the teachings of this disclosure shall prevail. The inventions described in the original claims of this application are listed below. [Invention 1] (a) CDR-L1, CDR-L2 and CDR-L3 compounds that specifically bind to human BCMA and are listed in Table 11A-1, Table 11B-1, Table 11C-1, Table 11D-1, Table 11E-1, Table 11F-1, Table 11G-1, Table 11H-1, Table 11I-1, Table 11J-1, Table 11K-1(a), Table 11K-1(b), Table 11L-1, Table 11M-1, Table 11N-1(a) or Table 11N-1(b) Antigen-binding module 1 (ABM1) containing the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in the columns and in Tables 11A-2, 11B-2, 11C-2, 11D-2, 11E-2, 11F-2, 11G-2, 11H-2, 11I-2, 11J-2, 11K-2, 11K-2, 11L-2, 11M-2, 11N-2, or 11N-2, respectively. (b) Antigen-binding module 2 (ABM2) that specifically binds to components of the human T cell receptor (TCR) complex; and (c) Antigen-binding module 3 (ABM3) that specifically binds to human CD2 or human tumor-associated antigen (TAA). Multiple specificity binding molecules (MBMs) that include these molecules. [Invention 2] ABM1 is the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11A-1, Table 11B-1, Table 11C-1, Table 11D-1, Table 11E-1, Table 11F-1, Table 11G-1, Table 11H-1, Table 11I-1, Table 11J-1, Table 11K-1(a), Table 11L-1, Table 11M-1 or Table 11N-1(a), and Table 11A The MBM according to Invention 1, comprising the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11B-2, Table 11C-2, Table 11D-2, Table 11E-2, Table 11F-2, Table 11G-2, Table 11H-2, Table 11I-2, Table 11J-2, Table 11K-2, Table 11L-2, Table 11M-2, or Table 11N-2, respectively. [Invention 3] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11A-1 and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11A-2. [Invention 4] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11B-1 and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11B-2. [Invention 5] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11C-1 and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11C-2. [Invention 6] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11D-1 and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11D-2. [Invention 7] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11E-1 and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11E-2. [Invention 8] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11F-1 and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11F-2. [Invention 9] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11G-1 and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11G-2. [Invention 10] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11H-1 and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11H-2. [Invention 11] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11I-1 and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11I-2. [Invention 12] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11J-1 and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11J-2. [Invention 13] ABM1 is an MBM according to Invention 1 or Invention 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11K-1(a) and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11K-2. [Invention 14] The MBM according to Invention 1, wherein ABM1 includes the CDR-L1, CDR-L2, and CDR-L3 sequences described in Table 11K-1(b), and the corresponding CDR-H1, CDR-H2, and CDR-H3 sequences described in Table 11K-2. [Invention 15] ABM1 is an MBM according to Invention 1 or 2, comprising the CDR-L1, CDR-L2, and CDR-L3 sequences described in